November 29, 2016 - By Hazel Jackson
Shareholder Matthias Alder of Sucampo Pharmaceuticals Inc, sold some 150,000 of the public firm shares worth $2,400,369 US Dollars with an average of $16.0 stock price per share. This trade was reported on November 28, 2016 and is already filed with the (SEC). The source 4F filing is available for review to the public here. That enormous stocks unloading is sure to get people talking for the company. Matthias Alder now has rights to 3,449 shares of the Firm.
Out of 9 analysts covering Sucampo Pharma (NASDAQ:SCMP), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. $31 is the highest target while $14 is the lowest. The $22.75 average target is 40.87% above today’s ($16.15) stock price. Sucampo Pharma has been the topic of 21 analyst reports since August 6, 2015 according to StockzIntelligence Inc. As per Thursday, August 4, the company rating was downgraded by Mizuho. The rating was upgraded by Mizuho on Wednesday, April 20 to “Buy”. The rating was maintained by Mizuho on Monday, January 18 with “Neutral”. The company was maintained on Thursday, August 27 by WallachBeth Capital. The rating was initiated by Mizuho on Friday, October 9 with “Neutral”. WallachBeth Capital maintained the shares of SCMP in a report on Thursday, August 6 with “Hold” rating. The firm has “Buy” rating given on Tuesday, February 9 by UBS. Mizuho maintained the shares of SCMP in a report on Monday, November 14 with “Neutral” rating. The rating was maintained by Jefferies on Wednesday, March 9 with “Hold”. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has “Mkt Perform” rating given on Thursday, September 3 by Leerink Swann.
Insitutional Activity: The institutional sentiment is 0.98 in Q2 2016. Its the same as in 2016Q1. The ratio is the same, as 17 funds sold all Sucampo Pharmaceuticals, Inc. shares owned while 46 reduced positions. only 22 funds bought stakes while 40 increased positions. They now own 17.83 million shares or 12.41% less from 20.36 million shares in 2016Q1.
Petrus Tru Company Lta holds 0.05% or 20,514 shares in its portfolio. The Ontario – Canada-based Manufacturers Life Insurance The has invested 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Tiaa Cref Investment Ltd Company reported 217,163 shares or 0% of all its holdings. Alliancebernstein Limited Partnership holds 54,962 shares or 0% of its portfolio. Piermont Capital Mngmt Inc has 61,499 shares for 0.17% of their US portfolio. Pnc Grp Inc owns 689 shares or 0% of their US portfolio. Qs Invsts Llc holds 138,700 shares or 0.01% of its portfolio. Barrett Asset Management Ltd Liability Company holds 7,800 shares or 0.01% of its portfolio. Swiss Bancorp holds 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 35,859 shares. The Pennsylvania-based Tfs Ltd Liability Corp has invested 0.32% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Blackrock Institutional Tru Na holds 653,762 shares or 0% of its portfolio. The New York-based Tower Research Cap Limited (Trc) has invested 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Blackrock Grp Incorporated Ltd accumulated 20,301 shares or 0% of the stock. Lsv Asset Mgmt holds 0.01% or 482,527 shares in its portfolio. Credit Suisse Ag holds 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 150,290 shares.
Insider Transactions: Since November 15, 2016, the stock had 0 insider buys, and 1 insider sale for $27,514 net activity. $27,514 worth of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) shares were sold by Smith Andrew P.
The stock increased 1.89% or $0.3 during the last trading session, hitting $16.15. About 1.84 million shares traded hands or 359.85% up from the average. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has risen 44.71% since April 26, 2016 and is uptrending. It has outperformed by 39.45% the S&P500.
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $747.34 million. The Firm focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology inflammatory disorders. It has a 54.28 P/E ratio. It operates through development and commercialization of pharmaceutical products segment.
According to Zacks Investment Research, “Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.”
Analysts await Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report earnings on March, 14. They expect $0.44 earnings per share, 0.00% or $0.00 from last year’s $0.44 per share. SCMP’s profit will be $20.36 million for 9.18 P/E if the $0.44 EPS becomes a reality. After $0.28 actual earnings per share reported by Sucampo Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 57.14% EPS growth.
More news for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) were recently published by: Bizjournals.com, which released: “Sucampo acquires exclusive option for cancer drug in deal worth up to $190 million” on January 11, 2016. Moodys.com‘s article titled: “Moody’s assigns B3 CFR to Sucampo Pharmaceuticals” and published on October 01, 2015 is yet another important article.
Sucampo Pharmaceuticals, Inc., incorporated on December 9, 2008, is a biopharmaceutical company. The Firm focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology inflammatory disorders. The Firm operates through development and commercialization of pharmaceutical products segment. The Company’s activities are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts activities in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, United Kingdom.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.